Top Line: Adding orteronel, a CYP17A1 inhibitor, to long term ADT and radiation does not improve outcomes for patients with high risk prostate cancer.
The Study: What is orteronel, you say? Orteronel, also called TAK-700, was a nonsteroidal CYP17A1 inhibitor. Abiraterone is also a CYP17A1 inhibitor, and these drugs work by blocking androgen biosynthesis. Orteronel was designed to be a more selective inhibitor with less effect on glucocorticoid synthesis and thus less need for co-administration of corticosteroids with treatment. RTOG 1115 was a randomized, phase 3 trial that sought to determine if more intensive androgen suppression with orteronel would improve outcomes in patients with high risk disease. Eligible patients met the following criteria: “1) Gleason score (GS) ≥ 9, PSA ≤ 150, any T-stage; 2) GS 8, PSA < 20, and ≥ T2; 3) GS 8, PSA 20-150, any T-stage; 4) GS 7, PSA 20-150, any T-stage.” They were randomized to receive RT + long term ADT with or without orteronel. RT consisted of 45 Gy in 25 fractions to the pelvis with a 34.2 Gy in 19 fraction boost (total 79.2 Gy in 44 fractions) or an HDR or LDR boost. The trial was closed early with only 231 of a planned 900 patients. At 5 years, there was no difference in OS with or without orteronel (88.1% v 90.4%) nor was there a difference in biochemical failure (12.8% v 17.3%). The biggest problem (besides low statistical power) was that orteronel was poorly tolerated with less than a third (29%) receiving at least 80% of the planned dose. This was because orteronel increased the rate of grade 3+ toxicity from 27.7% to 47.8%.
TBL: In RTOG 1115, more intensive androgen suppression with orteronel was poorly tolerated resulting in increased toxicity and no improvement in treatment outcomes among patients receiving dose-escalated RT and ADT for high risk prostate cancer. | Hamstra, Int J Radiat Oncol Biol Phys 2025
The Study: What is orteronel, you say? Orteronel, also called TAK-700, was a nonsteroidal CYP17A1 inhibitor. Abiraterone is also a CYP17A1 inhibitor, and these drugs work by blocking androgen biosynthesis. Orteronel was designed to be a more selective inhibitor with less effect on glucocorticoid synthesis and thus less need for co-administration of corticosteroids with treatment. RTOG 1115 was a randomized, phase 3 trial that sought to determine if more intensive androgen suppression with orteronel would improve outcomes in patients with high risk disease. Eligible patients met the following criteria: “1) Gleason score (GS) ≥ 9, PSA ≤ 150, any T-stage; 2) GS 8, PSA < 20, and ≥ T2; 3) GS 8, PSA 20-150, any T-stage; 4) GS 7, PSA 20-150, any T-stage.” They were randomized to receive RT + long term ADT with or without orteronel. RT consisted of 45 Gy in 25 fractions to the pelvis with a 34.2 Gy in 19 fraction boost (total 79.2 Gy in 44 fractions) or an HDR or LDR boost. The trial was closed early with only 231 of a planned 900 patients. At 5 years, there was no difference in OS with or without orteronel (88.1% v 90.4%) nor was there a difference in biochemical failure (12.8% v 17.3%). The biggest problem (besides low statistical power) was that orteronel was poorly tolerated with less than a third (29%) receiving at least 80% of the planned dose. This was because orteronel increased the rate of grade 3+ toxicity from 27.7% to 47.8%.
TBL: In RTOG 1115, more intensive androgen suppression with orteronel was poorly tolerated resulting in increased toxicity and no improvement in treatment outcomes among patients receiving dose-escalated RT and ADT for high risk prostate cancer. | Hamstra, Int J Radiat Oncol Biol Phys 2025

